SCHEMBL542074

SCHEMBL542074

CS(=O)(=O)Nc1ccccc1Nc1nc(Cl)ncc1F

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GLO1 Q04760 4/20 0.69
GSK3A P49840 1/20 0.48
LRRK2 Q5S007 1/20 0.48
MAPK15 Q8TD08 1/20 0.48
CAMKK2 Q96RR4 1/20 0.48
PIN1 Q13526 1/20 0.46
PTGS1 P23219 2/20 0.46
PTGS2 P35354 2/20 0.46
AURKA O14965 4/20 0.46
AURKB Q96GD4 3/20 0.46
MET P08581 2/20 0.43
ALK Q9UM73 2/20 0.43
PTK2 Q05397 1/20 0.43
EGFR P00533 2/20 0.42
YTHDC1 Q96MU7 1/20 0.42
JAK2 O60674 2/20 0.41
ROS1 P08922 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30942603 1.00 GLO1 (0.69) GLO1GSK3ALRRK2MAPK15CAMKK2
SCHEMBL10074538 0.87 GLO1 (0.55) GLO1GSK3ALRRK2MAPK15CAMKK2
SCHEMBL29435445 0.86 ALK (0.54) GLO1LRRK2PIN1PTGS1PTGS2
SCHEMBL542158 0.86 ALK (0.54) GLO1LRRK2PIN1PTGS1PTGS2
SCHEMBL601598 0.86 GLO1 (0.54) GLO1GSK3ALRRK2MAPK15CAMKK2
SCHEMBL656107 0.85 GLO1 (0.78) GLO1GSK3ALRRK2MAPK15CAMKK2
SCHEMBL30942610 0.85 GLO1 (0.52) GLO1PIN1PTGS1PTGS2MET
SCHEMBL1076995 0.85 GLO1 (0.52) GLO1PIN1PTGS1PTGS2MET
SCHEMBL30942614 0.85 GLO1 (0.52) GLO1AURKAAURKB
SCHEMBL600898 0.84 GLO1 (0.51) GLO1PIN1PTGS1PTGS2MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113896744-B Selective EGFR inhibitor 成都先导药物开发股份有限公司 2024-04-16 CN disclosed
WO-2023014022-A1 PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT 한국화학연구원 2023-02-09 WO disclosed
EP-2414337-B1 Methods for the identification of kinase interacting molecules and for the purification of kinase proteins CELLZOME GMBH (DE) 2013-05-01 EP disclosed
EP-2414337-B1 Methods for the identification of kinase interacting molecules and for the purification of kinase proteins CELLZOME GMBH (DE) 2013-05-01 EP disclosed
US-20120270237-A9 METHODS FOR THE IDENTIFICATION OF KINASE INTERACTING MOLECULES AND FOR THE PURIFICATION OF KINASE PROTEINS Cellzone AG (DE) 2012-10-25 US disclosed
US-20120270237-A9 METHODS FOR THE IDENTIFICATION OF KINASE INTERACTING MOLECULES AND FOR THE PURIFICATION OF KINASE PROTEINS Cellzone AG (DE) 2012-10-25 US disclosed
EP-2475648-A1 ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS Cellzome Limited (GB) 2012-07-18 EP disclosed
US-20120172385-A1 ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS CELLZOME LIMITED (GB) 2012-07-05 US disclosed
US-20120172384-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2012-07-05 US disclosed
US-20120172385-A1 ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS CELLZOME LIMITED (GB) 2012-07-05 US disclosed
WO-2010146133-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2010-12-23 WO disclosed
WO-2010142766-A2 PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2010-12-16 WO disclosed
WO-2010142766-A2 PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2010-12-16 WO disclosed
WO-2010118986-A1 FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS CELLZOME LIMITED (GB) 2010-10-21 WO disclosed
WO-2010118986-A1 FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS CELLZOME LIMITED (GB) 2010-10-21 WO disclosed
WO-2010112210-A1 METHODS FOR THE IDENTIFICATION OF KINASE INTERACTING MOLECULES AND FOR THE PURIFICATION OF KINASE PROTEINS CELLZOME AG (DE) 2010-10-07 WO disclosed
WO-2009127642-A2 USE OF LRRK2 INHIBITORS FOR NEURODEGENERATIVE DISEASES CELLZOME LIMITED (GB) 2009-10-22 WO disclosed
WO-2009127642-A2 USE OF LRRK2 INHIBITORS FOR NEURODEGENERATIVE DISEASES CELLZOME LIMITED (GB) 2009-10-22 WO disclosed
WO-2009112490-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2009-09-17 WO disclosed
WO-2009112490-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270237-A9 METHODS FOR THE IDENTIFICATION OF KINASE INTERACTING MOLECULES AND FOR THE PURIFICATION OF KINASE PROTEINS PACSIN2, SBK3, MKNK2 GLO1 3304/4885GSK3A 650/4885LRRK2 840/4885
US-20120172384-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS ZAP70, JAK3, JAK2 GLO1 3371/4885GSK3A 694/4885LRRK2 1177/4885
US-20120172385-A1 ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS JAK3, JAK1, JAK2 GLO1 4285/4885GSK3A 556/4885LRRK2 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.